Annexin A5 derived from matrix vesicles protects against osteoporotic bone loss via mineralization.
Guanyue SuDemao ZhangTiantian LiTong PeiJie YangShasha TuSijun LiuJie RenYaojia ZhangMengmeng DuanXinrui YangYang ShenChenchen ZhouJing XieXiaoheng LiuPublished in: Bone research (2023)
Matrix vesicles (MVs) have shown strong effects in diseases such as vascular ectopic calcification and pathological calcified osteoarthritis and in wound repair of the skeletal system due to their membranous vesicle characteristics and abundant calcium and phosphorus content. However, the role of MVs in the progression of osteoporosis is poorly understood. Here, we report that annexin A5, an important component of the matrix vesicle membrane, plays a vital role in bone matrix homeostasis in the deterioration of osteoporosis. We first identified annexin A5 from adherent MVs but not dissociative MVs of osteoblasts and found that it could be sharply decreased in the bone matrix during the occurrence of osteoporosis based on ovariectomized mice. We then confirmed its potential in mediating the mineralization of the precursor osteoblast lineage via its initial binding with collagen type I to achieve MV adhesion and the subsequent activation of cellular autophagy. Finally, we proved its protective role in resisting bone loss by applying it to osteoporotic mice. Taken together, these data revealed the importance of annexin A5, originating from adherent MVs of osteoblasts, in bone matrix remodeling of osteoporosis and provided a new strategy for the treatment and intervention of bone loss.
Keyphrases
- bone loss
- bone mineral density
- postmenopausal women
- body composition
- randomized controlled trial
- risk assessment
- signaling pathway
- single cell
- cell death
- rheumatoid arthritis
- type diabetes
- adipose tissue
- chronic kidney disease
- cystic fibrosis
- metabolic syndrome
- insulin resistance
- combination therapy
- wild type
- big data
- bone regeneration
- dna binding
- surgical site infection